Skip to main content

Table 3 Univariable analyses of PFS and OS

From: Combined prognostic value of the SUVmax derived from FDG-PET and the lymphocyte-monocyte ratio in patients with stage IIIB-IV non-small cell lung cancer receiving chemotherapy

Variables PFS OS
HR 95% CI p value HR 95% CI p value
Age (years)    0.015*    0.008**
  ≤ 65 Ref.    Ref.   
 >65 1.567 1.093–2.248   1.666 1.142–2.429  
Sex    0.174    0.365
 Male 1.320 0.885–1.968   1.216 0.796–1.859  
 Female Ref.    Ref.   
Smoking    0.391    0.717
 Never Ref.    Ref.   
 Ever 1.168 0.819–1.665   1.070 0.741–1.547  
ECOG PS    0.007**    0.019*
 0 Ref.    Ref.   
 1 1.610 1.136–2.283   1.548 1.073–2.234  
Lesion type    0.086    0.443
 Peripheral Ref.    Ref.   
 Central 1.357 0.958–1.922   1.152 0.802–1.655  
Histological type    0.835    0.816
 Adenocarcinoma Ref.    Ref.   
 Squamous 1.038 0.728–1.482   0.957 0.661–1.386  
Clinical stage    0.017*    0.045*
 IIIB Ref.    Ref.   
 IV 1.529 1.078–2.168   1.450 1.008–2.086  
First-line response    < 0.001***    < 0.001***
 CR/PR Ref.    Ref.   
 SD/PD 2.725 1.905–3.898   2.966 2.044–4.306  
CEA    0.280    0.719
 Normal 1.219 0.851–1.746   1.071 0.737–1.557  
 Increased Ref.    Ref.   
Albumin    0.023*    0.140
 Decreased 1.521 1.059–2.183   1.323 0.913–1.918  
 Normal Ref.    Ref.   
WBC    0.098    0.158
  ≤ 7.8 Ref.    Ref.   
 >7.8 1.337 0.948–1.887   1.297 0.904–1.860  
LMR    < 0.001***    < 0.001***
  ≤ 3.73 2.373 1.643–3.429   2.437 1.659–3.579  
 >3.73 Ref.    Ref.   
NLR    0.064    0.067
  ≤ 2.67 Ref.    Ref.   
 >2.67 1.395 0.981–1.984   1.403 0.977–2.017  
PLR    0.107    0.101
  ≤ 164 Ref.    Ref.   
 >164 1.342 0.939–1.918   1.361 0.942–1.968  
SUVmax    < 0.001***    < 0.001***
  ≤ 11.6 Ref.    Ref.   
 >11.6 2.400 1.674–3.440   2.976 2.024–4.375  
LMR_SUV    < 0.001***    < 0.001***
 Score 0 Ref.    Ref.   
 Score 1 2.228 1.383–3.590 0.001** 2.426 1.441–4.085 0.001**
 Score 2 4.449 2.719–7.281 < 0.001*** 5.361 3.172–9.058 < 0.001***
  1. PFS progression-free survival, OS overall survival, ECOG PS Eastern Cooperative Oncology Group Performance Status, CR complete response, PR partial response, SD stable disease, PD progressive disease, CEA carcinoembryonic antigen, WBC white blood cell, LMR lymphocyte-monocyte ratio, NLR neutrophil-lymphocyte ratio, PLR platelet-lymphocyte ratio, SUVmax maximum standardized uptake value, HR hazard ratio, CI confidence intervals. *, p < 0.05; **, p < 0.01; ***, p < 0.001